Vertex Pharmaceuticals Incorporated $VRTX Stake Lifted by Somerville Kurt F

Somerville Kurt F raised its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.4% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 23,186 shares of the pharmaceutical company’s stock after buying an additional 310 shares during the quarter. Vertex Pharmaceuticals makes up about 1.7% of Somerville Kurt F’s investment portfolio, making the stock its 24th largest holding. Somerville Kurt F’s holdings in Vertex Pharmaceuticals were worth $10,322,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Advisor OS LLC lifted its position in Vertex Pharmaceuticals by 4.4% in the 1st quarter. Advisor OS LLC now owns 543 shares of the pharmaceutical company’s stock valued at $263,000 after purchasing an additional 23 shares during the last quarter. Avidian Wealth Enterprises LLC increased its stake in shares of Vertex Pharmaceuticals by 2.1% in the first quarter. Avidian Wealth Enterprises LLC now owns 1,225 shares of the pharmaceutical company’s stock valued at $594,000 after purchasing an additional 25 shares during the period. Strategic Blueprint LLC increased its stake in shares of Vertex Pharmaceuticals by 1.7% in the first quarter. Strategic Blueprint LLC now owns 1,498 shares of the pharmaceutical company’s stock valued at $726,000 after purchasing an additional 25 shares during the period. Newman Dignan & Sheerar Inc. raised its holdings in shares of Vertex Pharmaceuticals by 3.3% during the second quarter. Newman Dignan & Sheerar Inc. now owns 786 shares of the pharmaceutical company’s stock valued at $350,000 after buying an additional 25 shares during the last quarter. Finally, Hager Investment Management Services LLC boosted its position in shares of Vertex Pharmaceuticals by 0.5% during the first quarter. Hager Investment Management Services LLC now owns 5,411 shares of the pharmaceutical company’s stock worth $2,623,000 after buying an additional 27 shares during the period. Institutional investors own 90.96% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on the company. Guggenheim lowered their target price on Vertex Pharmaceuticals from $558.00 to $546.00 and set a “buy” rating on the stock in a research report on Wednesday, August 6th. Raymond James Financial initiated coverage on Vertex Pharmaceuticals in a report on Tuesday, September 2nd. They set a “market perform” rating on the stock. Wall Street Zen cut shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 22nd. Scotiabank decreased their target price on shares of Vertex Pharmaceuticals from $442.00 to $438.00 and set a “sector perform” rating for the company in a research report on Tuesday, August 5th. Finally, Leerink Partnrs upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, September 25th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and twelve have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $493.81.

Vertex Pharmaceuticals Trading Up 1.8%

Shares of Vertex Pharmaceuticals stock opened at $410.28 on Wednesday. Vertex Pharmaceuticals Incorporated has a 52 week low of $362.50 and a 52 week high of $519.88. The stock has a market cap of $105.19 billion, a PE ratio of 29.33 and a beta of 0.43. The company’s 50-day moving average price is $396.79 and its two-hundred day moving average price is $441.11.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The company had revenue of $2.94 billion for the quarter, compared to analysts’ expectations of $2.90 billion. During the same quarter in the previous year, the company posted ($12.83) EPS. The business’s revenue was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Insider Activity

In related news, Director Bruce I. Sachs purchased 5,000 shares of the company’s stock in a transaction on Wednesday, August 6th. The shares were bought at an average price of $389.68 per share, with a total value of $1,948,400.00. Following the completion of the acquisition, the director owned 45,000 shares of the company’s stock, valued at approximately $17,535,600. This represents a 12.50% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.